» Articles » PMID: 22642910

Low α(2)β(1) Integrin Function Enhances the Proliferation of Fibroblasts from Patients with Idiopathic Pulmonary Fibrosis by Activation of the β-catenin Pathway

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 2012 May 31
PMID 22642910
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive and incurable fibroproliferative disorder characterized by unrelenting proliferation of fibroblasts and their deposition of collagen within alveoli, resulting in permanently scarred, nonfunctional airspaces. Normally, polymerized collagen suppresses fibroblast proliferation and serves as a physiological restraint to limit fibroproliferation after tissue injury. The IPF fibroblast, however, is a pathologically altered cell that has acquired the capacity to elude the proliferation-suppressive effects of polymerized collagen. The mechanism for this phenomenon remains incompletely understood. Here, we demonstrate that expression of α(2)β(1) integrin, a major collagen receptor, is pathologically low in IPF fibroblasts interacting with polymerized collagen. Low integrin expression in IPF fibroblasts is associated with a failure to induce PP2A phosphatase activity, resulting in abnormally high levels of phosphorylated (inactive) GSK-3β and high levels of active β-catenin in the nucleus. Knockdown of β-catenin in IPF fibroblasts inhibits their ability to proliferate on collagen. Interdiction of α(2)β(1) integrin in control fibroblasts reproduces the IPF phenotype and leads to the inability of these cells to activate PP2A, resulting in high levels of phosphorylated GSK-3β and active β-catenin and in enhanced proliferation on collagen. Our findings indicate that the IPF fibroblast phenotype is characterized by low α(2)β(1) integrin expression, resulting in a failure of integrin to activate PP2A phosphatase, which permits inappropriate activation of the β-catenin pathway.

Citing Articles

A roadmap for developing and engineering pulmonary fibrosis models.

Dabaghi M, Carpio M, Saraei N, Moran-Mirabal J, Kolb M, Hirota J Biophys Rev (Melville). 2024; 4(2):021302.

PMID: 38510343 PMC: 10903385. DOI: 10.1063/5.0134177.


Small-Molecule Activation of Protein Phosphatase 2A Counters Bleomycin-Induced Fibrosis in Mice.

Pillai M, Lafortune P, Dabo A, Yu H, Park S, Taluru H ACS Pharmacol Transl Sci. 2023; 6(11):1659-1672.

PMID: 37974628 PMC: 10644462. DOI: 10.1021/acsptsci.3c00117.


Protein Phosphatase 2A as a Therapeutic Target in Pulmonary Diseases.

Yu H, Zaveri S, Sattar Z, Schaible M, Perez Gandara B, Uddin A Medicina (Kaunas). 2023; 59(9).

PMID: 37763671 PMC: 10535831. DOI: 10.3390/medicina59091552.


Integrin β1 is a key determinant of the expression of angiotensin-converting enzyme 2 (ACE2) in the kidney epithelial cells.

Mia M, Hossain D, Woodbury E, Kelleher S, Palamuttam R, Rao R Eur J Cell Biol. 2023; 102(2):151316.

PMID: 37084657 PMC: 11086052. DOI: 10.1016/j.ejcb.2023.151316.


Hypoxia enhances IPF mesenchymal progenitor cell fibrogenicity via the lactate/GPR81/HIF1α pathway.

Yang L, Gilbertsen A, Xia H, Benyumov A, Smith K, Herrera J JCI Insight. 2023; 8(4).

PMID: 36656644 PMC: 9977506. DOI: 10.1172/jci.insight.163820.


References
1.
. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000; 161(2 Pt 1):646-64. DOI: 10.1164/ajrccm.161.2.ats3-00. View

2.
Xia H, Khalil W, Kahm J, Jessurun J, Kleidon J, Henke C . Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis. Am J Pathol. 2010; 176(6):2626-37. PMC: 2877826. DOI: 10.2353/ajpath.2010.091117. View

3.
Ruoslahti E . Integrin signaling and matrix assembly. Tumour Biol. 1996; 17(2):117-24. DOI: 10.1159/000217975. View

4.
Rhudy R, McPherson J . Influence of the extracellular matrix on the proliferative response of human skin fibroblasts to serum and purified platelet-derived growth factor. J Cell Physiol. 1988; 137(1):185-91. DOI: 10.1002/jcp.1041370123. View

5.
Fukuda Y, Ishizaki M, Masuda Y, Kimura G, Kawanami O, Masugi Y . The role of intraalveolar fibrosis in the process of pulmonary structural remodeling in patients with diffuse alveolar damage. Am J Pathol. 1987; 126(1):171-82. PMC: 1899540. View